Raphael Landovitz, MD
Enriched profileChief, UCLA Division of Infectious Diseases; Associate Vice Chair for Clinical Research, UCLA Department of Medicine; Professor of Medicine (effective March 1, 2025) · David Geffen School of Medicine at UCLA
Raphael Landovitz is Chief, UCLA Division of Infectious Diseases; Associate Vice Chair for Clinical Research, UCLA Department of Medicine; Professor of Medicine (effective March 1, 2025) at David Geffen School of Medicine at UCLA. OpenAlex indexes 216 publications with 9,026 citations (h-index 42); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Raphael J. Landovitz, MD, is Chief, UCLA Division of Infectious Diseases at David Geffen School of Medicine at UCLA / UCLA Health, Los Angeles, CA. The public record shows 216 publications with 9,026 citations (h-index 42), centered on HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, HIV Research and Treatment. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 6 companies, 4 NIH-funded awards (2009–2026).
- Most recent indexed publication: 2026 · Clinical infectious diseases
- Top research focus: HIV/AIDS Research and Interventions
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 107.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
Sponsor: University of California, Los Angeles
- Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Sponsor: Calimmune, Inc.
Industry payments
Updated 27 Aug 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202520 payments$14,541openpaymentsdata.cms.gov ↗
- ViiV Healthcare CompanyProgram year20254 payments$11,616openpaymentsdata.cms.gov ↗
- ViiV Healthcare CompanyProgram year202420 payments$41,767openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
78%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor40%Triumeq55%Descovy45%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor20%Tivicay100%Part D<11 patientsCardiovascular
22%Statin22%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- HIV Prevention Trials Network Leadership and Operations Center
Family Health International
FY2026$39,569,992UM1AI068619 - UCLA AIDS Prevention and Treatment Clinical Trials Unit
University of California Los Angeles
FY2026$3,163,461UM1AI069424 - Center for HIV Identification, Prevention and Treatment Services
University of California Los Angeles
FY2026$1,499,315P30MH058107
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083.
Clinical infectious diseases
Article2026 - Providing the Best Infectious Diseases and Primary Care to Our Patients With HIV: Time for Delivery Models to Evolve.
Clinical infectious diseases
Article2026 - Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083.
Clinical infectious diseases
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/raphael-landovitz-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Raphael-Landovitz
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/raphael-landovitz-346686140
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
chipts.ucla.edu/people/raphael-j-landovitz-m-d-m-sc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →chipts.ucla.edu ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗
Editorial & leadership roles
journal and society appointments- Executive Committee
HIV Prevention Trials Network (HPTN)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →chipts.ucla.edu ↗ - Peer reviewer
Clinical Infectious Diseases and Nature Reviews Microbiology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Ward Cates Award2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connect.uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iasusa.org ↗
- Co-director
UCLA Center for HIV Identification, Prevention and Treatment Services (CHIPTS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connect.uclahealth.org ↗ - Mary D. Fisher Endowed Chair in HIV Care
Treatment, and Prevention
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uclahealth.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Finn, MD
David Geffen School of Medicine at UCLA
Edward Garon, MD
David Geffen School of Medicine at UCLA
Donald Tashkin, MD
David Geffen School of Medicine at UCLA
Aditya Bardia, MD
David Geffen School of Medicine at UCLA